A1C decreased by
in the Lantus® and insulin detemir treatment groups and was comparable among groups after 52 weeks (7.1% for Lantus® and 7.2% for insulin detemir)
52% of participants in the study achieved A1C ≤7%
An open-label, parallel-group, noninferiority trial of 582 insulin-naive patients with type 2 diabetes. Patients were randomized 1:1 to receive Lantus® (n=291) or insulin detemir (n=291) once daily (in the evening) as add-on therapy to oral glucose-lowering drugs. Both insulins were titrated to an FPG target of ≤108 mg/dL. An additional morning insulin dose of insulin detemir was allowed if pre-dinner PG was >126 mg/dL, but only if pre-breakfast PG was <126 mg/dL or nocturnal hypoglycemia (major episode or PG ≤72 mg/dL) precluded achievement of the FPG target. Participants were eligible if A1C ranged from 7.5% to 10%. Primary endpoint was change in A1C at end of treatment period.
*Eligibility Restrictions & Offer Terms:
This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs, or commercial / private insurance. Only people without prescription medication insurance can apply for this offer. Void where prohibited by law. For the duration of the program, eligible patients will pay $99 for up to 10 vials or packs of pens per fill. Offer valid for one fill per month. To pay $99 per month, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. Not valid for SOLIQUA 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL or Toujeo Max SoloStar pen. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment